MannKind (MNKD) Presents Pediatric Insulin Trial Data
During a 'Future Ready' symposium, Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will share results from the randomized period of the INHALE-1 clinical trial. Dr. Haller also serves as the Chair for MannKind Corporation's (NASDAQ:MNKD) Phase 3 INHALE-1 study of Afrezza, an inhaled insulin powder, in children and adolescents between 4 and 17 years old.
A close-up of a doctor's hand pressing on an inhaler, conveying the effect of the company's therapeutic products.
MannKind Corporation (NASDAQ:MNKD) aims to release the topline results from the full pediatric study with safety extension in the second quarter of 2025. The company also expects to submit a Supplemental Biologics License Application in mid-2025 for a possible pediatric indication for Afrezza.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for those living with endocrine and orphan lung diseases.
While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Illinois veteran bestowed military honors nearly a decade after death
CHICAGO — Standing near the gravestone for the relative he never met, Mark Bailey accepted the crisply folded American flag from the Army officer, hugged it to his chest and closed his eyes. Though the person he called his aunt — born Reba Caroline Bailey — had been estranged, missing for decades and died in 2015 as an unidentified ward of the state, he felt connection and a sense of closure. 'I want to let Reba know we're part of the circle and part of the family,' he said. Mark Bailey was among dozens of attendees at an unusual funeral service with military honors this week for an Illinois veteran with memory problems so severe that they died an unnamed person. The ceremony became possible because of an extraordinary cold case investigation that identified the 75-year-old postmortem. Investigators unearthed the mystery of how the Women's Army Corps veteran ended up homeless in Chicago with few recollections of their own life, aside from identifying as a man named Seven. 'I never knew I had this family member,' said Mark Bailey's 19-year-old son Cole, who also drove from central Illinois for the service. 'It's nice to know I have somebody that's been found and isn't lost anymore.' Since the investigation's conclusion, the numbered cement cylinder that marked the unidentified grave has been replaced with a rectangular plague with a cross that reads: 'Reba Caroline Bailey, PFC US Army.' The case of Seven Doe, the name appearing in some official records, came to Cook County Sheriff Tom Dart's office in 2023. The unidentified body belonged to a person who died of natural causes in an assisted living facility. They were a ward of the state, unable to remember a legal name or family. The cause of death was heart disease with diabetes and dementia as contributing factors and the body was buried in a section for unclaimed people at Mount Olivet Catholic Cemetery on Chicago's Far South Side. The medical examiner marked it as the 4,985th case of the year and put the number on the headstone. In 2023, investigators ran fingerprints taken postmortem and found a 1961 Army record for the veteran, formerly of Danville, about 140 miles (225.31 kilometers) south of Chicago. The search for close living relatives came up short; five siblings and an ex-husband had all died. The family members they did locate had only heard stories of a relative who had disappeared. After making the identification, detectives ordered a new headstone with the same name on military records. It was quietly installed last year. Commander Jason Moran, who oversees the sheriff's missing persons unit, said it was rewarding to make sure the identified veteran got the benefit of a funeral with military honors. 'It's just a privilege to be able to help families and really close the story,' said Moran, whose work on other high-profile cold cases has gained notoriety. Several generations of the Bailey family have told stories about what happened to their missing relative since leaving the military to get married. They've wondered about the possibility of children or their relative's gender identity. Some believe that there was a family dispute but the stories about its origins vary from the decision to join the military to sexual orientation. Family members tried to find their missing relative over the years, including Amanda Ingram, who would have been a great-niece. She maintains a meticulous family tree with Census records and photos. 'It's amazing how somebody can just disappear like that and not know what happened,' Ingram said this week. 'I'm pretty sure we're never going to know the details.' On a winter day in the late 1970s, a person wearing a military-style jacket and aviator cap was curled up on the porch of St. Francis Catholic Worker House in Chicago. Residents who stayed there at the time told The Associated Press that the person asked to be called Seven, spoke in the third person and identified as a man. Seven quickly became the house cook. The meals drew crowds to the neighborhood where several homeless advocacy groups operated, according to former residents' accounts. Investigators have tried to explain the memory loss and floated theories about brain damage related to a 1950 car accident that killed Bailey's mother or to military service. That included stints at Fort Ord in California, a polluted former Army base, and Fort McClellan in Alabama, formerly used for chemical weapons training, and where the federal government has acknowledged potential exposure to toxins. Neither family, investigators nor residents of the worker house figured out the meaning behind the name Seven. Ingram, who lives in Alabama, couldn't make the ceremony this week. But she asked volunteers from an Illinois chapter of Daughters of the American Revolution to attend on her behalf. 'Everybody who comes to visit that cemetery will pass by it and know who she was,' said Ingram, whose detailed family trees include records using Bailey's birth name. Mark Bailey said he and his son wanted to bring something to the service that would honor both parts of their long-lost relative's life. They had heard their relative had an affinity for the Cubs and looked for a jersey with the number '7' on it, but settled on a blue team cap. They set it on the headstone. The service held Tuesday included prayers, a 21-gun salute and a bugler playing taps — a chilling, 24-note salute that is traditionally played at funerals of U.S. military veterans. Attendees included Cook County sheriff's investigators and Archdiocese of Chicago staff. 'I just wish the rest of them could be identified as well,' Mark Bailey told those attending while pointing to the rows of unidentified graves. Dart, the Cook County sheriff, said the ceremony left him nearly speechless, saying the Illinois veteran deserved military honors and a flag from the U.S. president 'instead of being forgotten and left as an anonymous number somewhere.' Relatives said they planned to eventually display the flag at the American Legion in Potomac, near where the Bailey family has roots. Mark Bailey said the acknowledgement of military service was particularly meaningful with so many veterans in the extended family. He hoped the memory would stay with his son Cole, who plans to enlist. 'For him, it'll be something he'll have forever,' he said.
Yahoo
19 minutes ago
- Yahoo
Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating
GeneDx Holdings Corp (NASDAQ:WGS) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp (NASDAQ:WGS) from $88.00 to $115.00, reinforcing a bullish stance on the company's long-term trajectory. The 'Buy' rating remains unchanged, signaling confidence in GeneDx's market position and its potential to capture a growing share of the precision medicine space. A modern office space where the team is engaging in business development and management services. GeneDx, known for its deep expertise in rare disease genomics and next-generation sequencing, is emerging as a leader in healthcare innovation. The company blends advanced bioinformatics with clinical expertise to help physicians diagnose complex, genetically driven conditions more efficiently. Its platform leverages massive datasets and machine learning algorithms to interpret whole-genome and exome sequencing, placing it squarely in the center of the healthcare AI movement. The price target hike reflects Guggenheim's view that GeneDx is well-positioned to benefit from the increasing demand for personalized medicine and the broader integration of data-driven tools in clinical care. As health systems and biopharma partners seek faster, more accurate diagnostic solutions, GeneDx's technology and scalable infrastructure make it a critical player in the shift toward AI-enabled healthcare. With momentum building across both clinical and commercial channels, the company appears to be gaining traction at a pivotal time for genomic medicine. The revised valuation underscores growing investor recognition of GeneDx's role in transforming how rare and complex diseases are diagnosed and managed. While we acknowledge the potential of WGS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WGS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating
iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Morgan Stanley has raised its price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $160 from $130, while maintaining an 'Overweight' rating, citing strong early indicators for the company's second-quarter performance. In a recent note to investors, the firm pointed to a surge in MyZio app downloads, which totaled 171,169 in Q2—up 74% year-over-year and 36% compared to the first quarter. The increase suggests iRhythm may outperform Street estimates, as most of the Zio patches generating revenue for the quarter have already been prescribed and tied to active monitoring. A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. Morgan Stanley highlighted that the strong app adoption signals growing patient engagement and broader acceptance of digital cardiac care, which bodes well for both short- and long-term growth. With scalable infrastructure and a rising volume of clinical data feeding its algorithms, iRhythm is not only improving detection but also redefining remote patient monitoring. As healthcare shifts toward personalized, tech-driven models, iRhythm's innovation and execution place it among the leaders in digital diagnostics. Morgan Stanley views the company as a compelling investment amid increasing demand for smart, connected health solutions. iRhythm Technologies, Inc. (NASDAQ:IRTC) develops and markets the Zio platform, a patch-based cardiac monitoring solution that leverages advanced analytics and machine learning to detect arrhythmias with clinical-grade accuracy. The company's AI-enabled technology analyzes millions of heartbeats in real time, helping physicians diagnose conditions like atrial fibrillation more effectively than traditional methods. While we acknowledge the potential of IRTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRTC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio
